Compare PEBK & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBK | PLX |
|---|---|---|
| Founded | 1912 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.4M | 182.9M |
| IPO Year | 2012 | 1996 |
| Metric | PEBK | PLX |
|---|---|---|
| Price | $43.90 | $2.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 36.3K | ★ 794.2K |
| Earning Date | 04-20-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | ★ 21.48 | N/A |
| EPS | ★ 1.76 | 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.63 | ★ $9.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.33 | $1.52 |
| 52 Week High | $45.78 | $3.19 |
| Indicator | PEBK | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 51.49 | 61.30 |
| Support Level | $41.53 | $2.18 |
| Resistance Level | $45.46 | $2.71 |
| Average True Range (ATR) | 1.02 | 0.13 |
| MACD | -0.11 | 0.02 |
| Stochastic Oscillator | 37.31 | 75.70 |
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.